Satellos Bioscience Inc. Cash Flow Conversion Efficiency
Satellos Bioscience Inc. cash flow conversion efficiency. Based on the latest financial reports, Satellos Bioscience Inc. (MSCL) has a cash flow conversion efficiency ratio of -0.131x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-7.83 Million ≈ $-5.66 Million USD) by net assets (CA$59.81 Million ≈ $43.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Satellos Bioscience Inc. (2007–2025)
Cash flow conversion efficiency of Satellos Bioscience Inc. from 2007 to 2025. This chart illustrates how Satellos Bioscience Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View MSCL stock price and chart for real-time trading data and today's change.
Satellos Bioscience Inc. Cash Flow Conversion Ratio Explained
Satellos Bioscience Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Satellos Bioscience Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Satellos Bioscience Inc. ranked by their cash flow conversion efficiency. Also see market cap of Satellos Bioscience Inc. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
King Polytechnic Engineering Co Ltd
TWO:6122
|
0.110x |
|
Bitcoin Group SE
XETRA:ADE
|
0.008x |
|
CYGNUS Metals Ltd
AU:CY5
|
-0.033x |
|
LG Household & Healthcare Ltd Pref
KO:051905
|
0.029x |
|
Capacit'e Infraprojects Limited
NSE:CAPACITE
|
0.028x |
|
Land General Bhd
KLSE:3174
|
0.065x |
|
Baozun Inc
NASDAQ:BZUN
|
0.000x |
|
Tucows Inc.
TO:TC
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Satellos Bioscience Inc. (2007–2025)
The table below shows the annual cash flow conversion efficiency of Satellos Bioscience Inc. from 2007 to 2025. Review MSCL free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$27.73 Million ≈ $20.06 Million |
CA$-24.01 Million ≈ $-17.37 Million |
-0.866x | -135.23% |
| 2024-12-31 | CA$67.86 Million ≈ $49.09 Million |
CA$-24.98 Million ≈ $-18.07 Million |
-0.368x | -3.83% |
| 2023-12-31 | CA$40.67 Million ≈ $29.42 Million |
CA$-14.42 Million ≈ $-10.43 Million |
-0.354x | +78.84% |
| 2022-12-31 | CA$3.37 Million ≈ $2.44 Million |
CA$-5.64 Million ≈ $-4.08 Million |
-1.675x | -248.79% |
| 2021-12-31 | CA$10.48 Million ≈ $7.58 Million |
CA$-5.03 Million ≈ $-3.64 Million |
-0.480x | -105.32% |
| 2020-12-31 | CA$-183.84K ≈ $-132.98K |
CA$-1.66 Million ≈ $-1.20 Million |
9.030x | +291.71% |
| 2019-12-31 | CA$408.57K ≈ $295.56K |
CA$-1.92 Million ≈ $-1.39 Million |
-4.710x | -366.32% |
| 2018-12-31 | CA$-624.38K ≈ $-451.67K |
CA$-1.10 Million ≈ $-798.83K |
1.769x | +407.07% |
| 2016-12-31 | CA$2.31 Million ≈ $1.67 Million |
CA$-1.33 Million ≈ $-963.36K |
-0.576x | +29.65% |
| 2015-12-31 | CA$3.78 Million ≈ $2.74 Million |
CA$-3.10 Million ≈ $-2.24 Million |
-0.819x | -59.16% |
| 2014-12-31 | CA$5.51 Million ≈ $3.99 Million |
CA$-2.84 Million ≈ $-2.05 Million |
-0.514x | +82.25% |
| 2013-12-31 | CA$1.30 Million ≈ $940.12K |
CA$-3.77 Million ≈ $-2.72 Million |
-2.898x | -115.11% |
| 2012-12-31 | CA$2.05 Million ≈ $1.48 Million |
CA$-2.76 Million ≈ $-2.00 Million |
-1.347x | -87.28% |
| 2011-12-31 | CA$2.69 Million ≈ $1.95 Million |
CA$-1.93 Million ≈ $-1.40 Million |
-0.719x | +35.67% |
| 2010-12-31 | CA$2.38 Million ≈ $1.73 Million |
CA$-2.67 Million ≈ $-1.93 Million |
-1.118x | -126.79% |
| 2009-12-31 | CA$4.29 Million ≈ $3.11 Million |
CA$-2.12 Million ≈ $-1.53 Million |
-0.493x | +78.84% |
| 2008-12-31 | CA$1.03 Million ≈ $745.64K |
CA$-2.40 Million ≈ $-1.74 Million |
-2.330x | -48.35% |
| 2007-12-31 | CA$2.49 Million ≈ $1.80 Million |
CA$-3.91 Million ≈ $-2.83 Million |
-1.570x | -- |
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small m… Read more